David Shanahan is the founder of Gradalis. Gradalis has raised $34M in total funding. Latest round: Growth. Backed by Ken Smith.
David Shanahan is the Founder, Chairman, and Chief Executive Officer of Gradalis, Inc., a biotechnology company focused on personalized cancer immunotherapies. He previously held an executive position at Prometheus before leading Gradalis. Under his leadership, Gradalis developed Vigil (gemogenovatucel-T), a DNA-based immunotherapy platform.
Full founder directory · Investor directory · Company funding database · Fundraising library